Association between beta2-microglobulin normalisation within 6 months of ibrutinib-based treatment and progression-free survival in patients with chronic lymphocytic leukaemia
Latest Information Update: 25 Nov 2015
At a glance
- Drugs Ibrutinib (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Pharmacodynamics
- 25 Nov 2015 New trial record
- 20 Nov 2015 Results published in the Cancer